(Reuters) -Analysts at J.P.Morgan on Thursday raised their 2023 growth forecast for China’s gross domestic product by 30 basis points…
Global investors fly blind into China’s messy post-COVID transition
By Summer Zhen and Samuel Shen HONG KONG/SHANGHAI (Reuters) – Global investors, already caught off guard by China’s virus-policy U-turn,…
China fuel demand outlook brightens as road, air traffic jump after COVID curbs ease
By Muyu Xu SINGAPORE (Reuters) – Road and air traffic in China, the world’s second-biggest oil consumer, has rebounded sharply…
Illumina defends $7.1 billion Grail buy to fend off antitrust regulators
By Diane Bartz WASHINGTON (Reuters) – U.S. life sciences company Illumina Inc on Tuesday defended its $7.1 billion acquisition of…
Eli Lilly prepares for as many as 5 new drug launches next year
By Leroy Leo (Reuters) -Eli Lilly and Co said on Tuesday it hopes to launch as many as five new…
Biden says inflation going down but do not take anything for granted
By Steve Holland and Nandita Bose WASHINGTON (Reuters) – President Joe Biden on Tuesday said inflation in the United States…
China delays key economic meeting amid COVID surge – Bloomberg News
(Reuters) -China is delaying a key economic meeting after COVID-19 infections surged in Beijing, according to a report by Bloomberg…
Cathay Pacific Airways aims to return to pre-pandemic levels by end-2024
HONG KONG (Reuters) – Hong Kong’s Cathay Pacific Airways Ltd said on Tuesday the group is on track to achieve…
Hit by COVID wave, companies in China strain to keep operations running normally
By Joe Cash, Ellen Zhang and Sophie Yu BEIJING (Reuters) – From e-commerce giant JD.com to cosmetics brand Sephora, companies…
Pfizer sees $10 billion-$15 billion in potential revenue from mRNA vaccines by 2030
(Reuters) -Pfizer Inc said on Monday annual revenue from its mRNA vaccine portfolio could reach $10 billion to $15 billion…